Skip to content

Latest expert network news

Stay up to date with the latest news from Techspert, and read updates and insights from the many industries we work in

Featured

Techspert's Milestone Achievement in the Financial Times 1000 List

Techspert's recognition as the 539th placement in the Financial Times 1000: Europe’s Fastest Growing Companies underscores our commitment to revolutionizing how expert insights are accessed and applied in the healthcare and life sciences sectors....

Read more

Latest Posts

Featured

6 Expert Network Platforms for Pharma Research and Due Diligence 2026

Running pharma primary research or healthcare investment due diligence means you need access to the right experts, fast. The challenge? Most expert network platforms for life sciences research rely on recycled databases, leaving your team with generic insights that competitors already have.

Read more
Featured

Data Capture is a core workflow on the Primary Research Platform

Many primary market research teams have an insight throughput problem. Calls happen. Value gets created. Then momentum dies in the manual work that follows. Grids are built by hand, quotes are hunted down again, formatting is repeated for different stakeholders, and validation loops drag internal reviews into the ground. This is the exact shift we’re leaning into with Data Capture. We’re continuing to invest in it, improving it, and making it more powerful for everyone, because the pain point is consistent across teams, and the work after the call is where capacity gets burned. Whether your calls happen in Techspert or elsewhere, the next step should be the same: a structured Q&A grid with the evidence, ready to share and build on.

Read more
Featured
,
Market Trends, Access & Sizing

November 2025 AI in Healthcare & Life Sciences: Strategy, Access & GTM Roundup

This month’s developments offer a clear view of where AI is gaining real traction in healthcare and life sciences. Much of the most substantive activity came through ESMO’s AI & Digital Oncology Congress and affiliated publications, which now function as one of the most active testing grounds for AI standards, clinical validation, and governance. That concentration is itself a signal: oncology remains the domain where evidence, infrastructure, and regulatory engagement with AI are maturing fastest. The signals highlight where AI has moved beyond experimentation and where strategic teams can start making informed updates to study design, diagnostic pathways, and market models. The focus throughout is on developments with clear implications for 2026 planning, access conversations, and scientific messaging.

Read more

All articles

Finding new voices for your market research

Start my project 

Mask Group 8